Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
3
75%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Recruiting1
Enrolling by invitation1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

completed125%
recruiting125%
enrolling_by_invitation125%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

NCT07396480
enrolling_by_invitationphase_3

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT05674539
terminatedphase_3

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

NCT01339910
completedphase_2

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

NCT01410344

Clinical Trials (4)

Showing 4 of 4 trials
NCT07396480Phase 3

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

Recruiting
NCT05674539Phase 3

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Enrolling By Invitation
NCT01339910Phase 3

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Terminated
NCT01410344Phase 2

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4